Garay-Aramburu, Gonzaga http://orcid.org/0000-0001-5255-8426
Hunt, Adrian http://orcid.org/0000-0002-6261-4679
Arruabarrena, Carolina http://orcid.org/0000-0002-5312-8900
Mehta, Hemal http://orcid.org/0000-0002-0606-9004
Invernizzi, Alessandro
Gabrielle, Pierre-Henry
Guillaumie, Tremeur
Wolff, Benjamin
Gillies, Mark C.
Zarranz-Ventura, Javier http://orcid.org/0000-0003-2338-8143
Funding for this research was provided by:
OSI BILBAO BASURTO ESI
Article History
Received: 13 November 2023
Accepted: 8 March 2024
First Online: 13 March 2024
Competing interests
: G.G-A: Consultant AJL; Participation on Data Safety Monitoring Board or Advisory Board AbbVie/Allergan. A.H.: Financial support Bayer. P.H.: has received travel expenses from Allergan/Abbvie, Roche, Bayer and Novartis, honoraria from Novartis and Bayer, and is a member of the medical advisory boards for Novartis, Bayer, Horus and Zeiss. H.M.: Honoraria AbbVie/Allergan, Bayer, Novartis, Roche; Financial support, Bayer, Novartis; Participation on Data Safety Monitoring Board or Advisory Board AbbVie/Allergan, Roche. B.W :Bayer, Horus, Abbvie, Roche. M.G.: Honoraria Bayer, Novartis, Roche. J.Z.V.: Honoraria e AbbVie/Allergan, Novartis, Roche, Bayer; Financial support AbbVie/Allergan, Novartis, Roche, Bayer; Participation on Data Safety Monitoring Board or Advisory Board AbbVie/Allergan, Novartis, Roche, Bayer; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid—Spanish Society of Retina and Vitreous, Catalunya´s Representative. The other authors have no proprietary or commercial interest in any materials discussed in this article.